Topics

Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

07:01 EST 4 Nov 2019 | FinanzNachrichten

- Supplemental Materials Will be Made Available on Alkermes' Website on Friday, Nov. 8 - DUBLIN, Nov. 4, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will present new d...

Original Article: Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

NEXT ARTICLE

More From BioPortfolio on "Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting"

Quick Search